KayoThera develops therapeutics used to cure late-stage and metastatic cancers.
KayoThera has raised $5.2M in total funding. The most recent round was Series A. The last funding was announced in July 2023.
KayoThera's investors include BioAdvance, Accelerator Life Science Partners, Pier 70 Ventures, National Institute of General Medical Science, WRF Capital.
KayoThera is headquartered in Princeton, United States.
KayoThera develops therapeutics used to cure late-stage and metastatic cancers.
KayoThera is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"KayoThera — Funding & Investors." VCBacked, July 19, 2023, https://www.vcbacked.co/company/kayothera. Accessed September 16, 2026.
VCBacked. (2023). KayoThera — Funding & Investors. Retrieved September 16, 2026, from https://www.vcbacked.co/company/kayothera
{{cite web |title=KayoThera — Funding & Investors |url=https://www.vcbacked.co/company/kayothera |website=VCBacked |access-date=September 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated